Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Moderate Buy” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned an average rating of “Moderate Buy” from the twenty brokerages that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $165.95.

A number of research firms recently weighed in on ILMN. Piper Sandler dropped their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. UBS Group lifted their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group upped their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th.

Illumina Price Performance

Shares of ILMN opened at $133.63 on Thursday. The firm has a market cap of $21.19 billion, a PE ratio of -13.42 and a beta of 1.11. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business’s 50 day moving average price is $142.19 and its two-hundred day moving average price is $131.04.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. Illumina’s revenue was down 3.5% on a year-over-year basis. On average, equities analysts anticipate that Illumina will post 4.11 EPS for the current year.

Institutional Investors Weigh In On Illumina

Large investors have recently modified their holdings of the stock. Industrial Alliance Investment Management Inc. purchased a new stake in Illumina in the second quarter worth $34,000. TD Private Client Wealth LLC increased its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Illumina in the 2nd quarter valued at about $61,000. Finally, Private Trust Co. NA lifted its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.